ERLOTINIB for Lung neoplasm malignant: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 9,207 adverse event reports in the FDA FAERS database where ERLOTINIB was used for Lung neoplasm malignant.
Most Reported Side Effects for ERLOTINIB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Death | 5,000 | 22.3% | 4,996 | 386 |
| Rash | 4,648 | 20.7% | 580 | 485 |
| Diarrhoea | 3,448 | 15.3% | 462 | 598 |
| Fatigue | 1,548 | 6.9% | 392 | 246 |
| Nausea | 1,366 | 6.1% | 284 | 290 |
| Drug ineffective | 1,207 | 5.4% | 159 | 101 |
| Off label use | 1,190 | 5.3% | 809 | 198 |
| Decreased appetite | 998 | 4.4% | 249 | 234 |
| Malignant neoplasm progression | 954 | 4.3% | 494 | 230 |
| Dry skin | 953 | 4.2% | 57 | 83 |
| Disease progression | 910 | 4.1% | 246 | 93 |
| Pruritus | 830 | 3.7% | 68 | 82 |
| Vomiting | 820 | 3.7% | 199 | 271 |
| Asthenia | 757 | 3.4% | 281 | 230 |
| Dyspnoea | 738 | 3.3% | 265 | 283 |
Other Indications for ERLOTINIB
Non-small cell lung cancer (3,359)
Product used for unknown indication (3,040)
Pancreatic carcinoma (1,089)
Malignant respiratory tract neoplasm (876)
Lung adenocarcinoma (841)
Neoplasm malignant (565)
Bronchial carcinoma (397)
Non-small cell lung cancer metastatic (290)
Lung adenocarcinoma stage iv (203)
Bone cancer (174)
Other Drugs Used for Lung neoplasm malignant
OSIMERTINIB (4,754)
NIVOLUMAB (4,197)
PEMBROLIZUMAB (3,575)
CARBOPLATIN (3,487)
ALECTINIB (2,932)
PEMETREXED (2,422)
CRIZOTINIB (1,949)
BEVACIZUMAB (1,810)
PACLITAXEL (1,747)
ATEZOLIZUMAB (1,262)